Our brand-new news section covers hot topics from the most important mergers and acquisitions, some significant drug approvals, investigations in the pharma sphere and major news in the world of oncology.
Keep up to date with the biggest news from the pharma world from pages 6 to 11.
Neurology is a key focus topic within this edition, exploring the advances in neurological research, as well as analysing the unmet needs in the field and its future. Many developments have already been made – for example, the use of AI and digital tech – but there is still a long way to go in understanding the needs of patients and in further advancing research techniques.
Rare diseases are difficult to diagnose and treat. As a result, there is constant research and analysis in this area, evident in the largest section of this edition. Rare disease research has long been neglected, in part due to its inherent difficulties. With rare diseases beginning to garner more attention, patient advocacy organisations - a powerful tool for rare diseases researchers - also deserve recognition in this space.
Heart disease is ranked as the largest cause of death worldwide, making research into novel treatments hugely important. Equally important is ensuring equivalent access to medicine and therapies in cardiovascular disease treatment, as vast inequalities have arisen since the COVID-19 pandemic began.
Pharmafile is published each Spring and Autumn. For subscription information, please contact us.
The opinions and views expressed by contributors in this book are not necessarily those of the Publisher and, while every care has been taken in the preparation of this book, the Publisher is not responsible for such opinion and views, or for any inaccuracies in the contributions and data it contains.
The Publisher is not responsible for any images or graphics supplied by contributors. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means, without prior permission from Samedan Ltd.